The firm published a study showing the technology could be used to determine antimicrobial susceptibility as well as minimum inhibitory concentrations.
The University of Toronto is developing a platform that enables swapping of various sensing technologies that could measure different analytes in a range of applications.
The firm used about $38.8 million on Feb. 1 to repay all outstanding principal, interest, related fees, and other obligations under an existing loan agreement.
The BioFire FilmArray Pneumonia panel will be used to optimize clinical trial enrollment for an antibiotic to treat combat carbapenem-resistant A. baumannii infections.
The firm said it expects to achieve full-year revenue of $100 million in 2023, based on its commercial and development opportunities and operational investments.
Qiagen's Q4 revenues of $403.2 million fell short of the consensus analyst estimate though its adjusted EPS of $.40 was in line with Wall Street expectations.
The researchers also determined that the two most widely used IGRAs used for diagnosing the disease in developed countries are not accurate for active TB.
Roche Diagnostics had sales of CHF 12.88 billion in 2018. For the fourth quarter, diagnostics sales totaled CHF 3.5 billion, up 10 percent year over year.
Researchers at Washington University in Saint Louis will use new funds to confirm preliminary findings on malaria-infected kids in a second location in Africa.
The firm expects to use the funding to meet demand for its Steripath platform, which improves accuracy, consistency, and predictability of diagnostic lab tests.
The funds will help commercialize Ador's NATlab reader, a point-of-care MDX platform for sample-to-answer identification of specific infectious diseases.
